Abstract:For patients diagnosed with advanced gastric or gastroesophageal cancer (AGC) that is not amenable to surgical intervention, the standard of care for first-line treatment consists of fluoropyrimidine and platinum-based chemotherapy. The incorporation of novel agents into these standard first-line regimens could potentially improve patient prognosis; options for such augmentations include both immune-based and targeted therapy combinations. To provide a comparative analysis of these different first-line combination treatments, a network meta-analysis was conducted. Outcome measures comprised overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and grade 3-4 treatment-related adverse events (TRAEs). Data were drawn from 22 randomized controlled trials, encompassing 10,787 patients and 17 distinct treatment regimens. Our findings suggest that FGFR2b-targeted therapy, specifically when used in combination with chemotherapy (bemarituzumab_chemo), exhibited the greatest efficacy. This was followed by immunotherapy-based combination regimens (CPS ≥5, Sintilimab_chemo). Further, targeted combination therapy featuring CLAUDIN 18.2 (zolbetuximab_chemo) appeared beneficial based on individual patient characteristics. In the case of HER2-positive patients, the trastuzumab_chemo regimen is recommended, as most existing studies have excluded this subpopulation. These results have significant implications for both clinical decision-making and patient care in the realm of advanced gastric or gastroesophageal cancer treatment.

HUMAN SPERM DNA DAMAGE IN THE CONTEXT OF ASSISTED REPRODUCTIVE TECHNIQUES

Logo Recognition by Consensus for Enabling Blockchain Implementations

Research progress of immune checkpoint inhibitors in neoadjuvant therapy of locally advanced gastric cancer

Immune checkpoint inhibitors combined with HER-2 targeted therapy in HER-2 positive gastroesophageal cancer

Current Status and Clinical Research Progress of Immunotherapy for Advanced Gastric Cancer

Immunotherapy and combined treatment in gastric cancer

Immunotherapy of Gastric Cancer: Past, Future Perspective and Challenges

Immune Checkpoint Inhibitors for Treatment of Advanced Gastric or Gastroesophageal Junction Cancer: Current Evidence and Future Perspectives

Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer

Research Progress of Immune Checkpoint Inhibitor in the Treatment of Gastric Cancer

Current status of immune checkpoint inhibitors for gastric cancer

Progress and prospects of biomarker-based targeted therapy and immune checkpoint inhibitors in advanced gastric cancer

Research Status and Progress on Treatment of Advanced Gastric Cancer

[The absence of stereoselectivity in propranolol uptake by the lungs].

Advances in immunotherapy for gastric cancer

Current status of neoadjuvant immunotherapy for the treatment of gastric cancer

Current status of immunotherapy in gastric cancer

Recent advances in immunotherapy and molecular targeted therapy for gastric cancer

Immune Checkpoint Inhibitors Combined with Targeted Therapy: the Recent Advances and Future Potentials

Recent developments in immunotherapy for gastrointestinal tract cancers

Immunotherapy and targeted therapy as first-line treatment for advanced gastric cancer